Research Topics
Genomes and GenesSpecies | John HeitSummaryAffiliation: Mayo Clinic Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
A genome-wide association study of venous thromboembolism identifies risk variants in chromosomes 1q24.2 and 9qJ A Heit
Division of Cardiovascular Diseases, Department of Internal Medicine Division of Biomedical Statistics and Informatics, Department of Health Sciences Research Division of Experimental Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
J Thromb Haemost 10:1521-31. 2012..05 and 0.5, respectively (α = 1 × 10(-8) ; 1% VTE prevalence). Conclusions: Apart from F5 rs6025, ABO rs8176719, rs2519093 and F2 rs1799963, additional common and high VTE-risk SNPs among whites are unlikely...- Predicting the risk of venous thromboembolism recurrenceJohn A Heit
Division of Cardiovascular Diseases, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA
Am J Hematol 87:S63-7. 2012..The appropriateness of secondary prophylaxis should be continuously reevaluated, and the prophylaxis stopped if the benefit no longer exceeds the risk... - Predictors of survival after deep vein thrombosis and pulmonary embolism: a population-based, cohort studyJ A Heit
Department of Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
Arch Intern Med 159:445-53. 1999.... - The epidemiology of venous thromboembolism in the communityJohn A Heit
Division of Cardiovascular Diseases (Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905, USA
Arterioscler Thromb Vasc Biol 28:370-2. 2008 - The epidemiology of venous thromboembolism in the community: implications for prevention and managementJohn A Heit
Coagulation Laboratories and Clinic, Mayo Clinic College of Medicine, Mayo Clinic and Mayo Foundation, 200 First Street SW, Rochester, MN 55905, USA
J Thromb Thrombolysis 21:23-9. 2006..Better individual risk stratification is needed in order to modify exposures and target primary and secondary prophylaxis to the person who would benefit most... - The potential role of direct thrombin inhibitors in the prevention and treatment of venous thromboembolismJohn A Heit
Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
Chest 124:40S-8S. 2003..Oral direct thrombin inhibitors may also be safe and effective, and offer enhanced convenience without diet or drug-drug interactions... - Cancer and venous thromboembolism: scope of the problemJohn A Heit
Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Cancer Control 12:5-10. 2005 - Venous thromboembolism: disease burden, outcomes and risk factorsJ A Heit
Division of Cardiovascular Diseases Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Thromb Haemost 3:1611-7. 2005..Better individual risk stratification is needed in order to modify exposures and target primary and secondary prophylaxis to the person who would benefit most... - Familial segregation of venous thromboembolismJ A Heit
Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
J Thromb Haemost 2:731-6. 2004..Venous thromboembolism (VTE) is postulated as a complex disease, but the heritability and mode of inheritance are uncertain... - Thrombomodulin gene polymorphisms or haplotypes as potential risk factors for venous thromboembolism: a population-based case-control studyJohn A Heit
Division of Cardiovascular Diseases, Mayo Clinic and Foundation, Rochester, MI, USA
J Thromb Haemost 3:710-7. 2005..Null genetic marker allele frequencies did not differ significantly among cases and controls. We conclude that polymorphisms or haplotypes within the TM gene are not common risk factors for incident VTE... - Comparison of characteristics from White- and Black-Americans with venous thromboembolism: a cross-sectional studyJohn A Heit
Mayo Clinic Thrombophilia Center, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Am J Hematol 85:467-71. 2010..The prevalence of transient VTE risk factors and idiopathic VTE among Blacks appears to be lower and higher, respectively, suggesting that heritability may be important in the etiology of VTE among Black-Americans... - Mapping out the future in venous thromboembolism and acute coronary syndromesJohn A Heit
Division of Cardiovascular Diseases, Section of Vascular Diseases, Department of Internal Medicine, Mayo Clinic and Foundation, Rochester, Minnesota 55905, USA
Semin Thromb Hemost 28:33-9. 2002.... - Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort studyJ A Heit
Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
Arch Intern Med 160:761-8. 2000..The appropriate duration of oral anticoagulation after a first episode of venous thromboembolism (VTE) is uncertain and depends upon VTE recurrence rates... - Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control studyJ A Heit
Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minn 55905, USA
Arch Intern Med 160:809-15. 2000..Reported risk factors for venous thromboembolism (VTE) vary widely, and the magnitude and independence of each are uncertain... - Trends in the incidence of venous stasis syndrome and venous ulcer: a 25-year population-based studyJ A Heit
Division of Cardiovascular Diseases, Section of Vascular Medicine, Mayo Clinic and Foundation, Rochester, MN 55905, USA
J Vasc Surg 33:1022-7. 2001..The incidence rates of venous stasis syndrome and venous ulcer are uncertain, and trends in incidence are unknown... - Low-molecular-weight heparin: the optimal duration of prophylaxis against postoperative venous thromboembolism after total hip or knee replacementJ A Heit
Division of Cardiovascular Diseases Section of Vascular Diseases, and the Division of Hematology Section of Hematology Research, Department of Internal Medicine Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
Thromb Res 101:V163-73. 2001..Future research should be directed at identifying patients at risk for out-of-hospital venous thromboembolism, and targeting extended prophylaxis to those at highest risk... - The incidence of venous thromboembolism among Factor V Leiden carriers: a community-based cohort studyJ A Heit
Division of Cardiovascular Diseases and Section of Haematology Research, Department of Internal Medicine, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905, USA
J Thromb Haemost 3:305-11. 2005..Among all carriers, those > or = 60 years old are at the highest risk for VTE. The incidence of VTE among asymptomatic women carriers during pregnancy is low and insufficient to warrant prophylaxis... - The epidemiology of venous thromboembolism in the communityJ A Heit
Division of Cardiovascular Diseases, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Thromb Haemost 86:452-63. 2001..To reduce venous thromboembolism incidence, improve survival, and prevent recurrence and complications, patients with these characteristics should receive appropriate prophylaxis... - Genetic variation within the anticoagulant, procoagulant, fibrinolytic and innate immunity pathways as risk factors for venous thromboembolismJ A Heit
Division of Cardiovascular Diseases, Department of Internal Medicine Division of Experimental Pathology, Department of Laboratory Medicine and Pathology Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN 55905, USA
J Thromb Haemost 9:1133-42. 2011..40. Conclusions: Anticoagulant, procoagulant, fibrinolytic and innate immunity pathway genetic variation accounts for a large proportion of VTE among non-Hispanic adults of European ancestry... - Heparin and warfarin anticoagulation intensity as predictors of recurrence after deep vein thrombosis or pulmonary embolism: a population-based cohort studyJohn A Heit
Division of Cardiovascular Diseases Section of Vascular Diseases, Mayo Clinic, Rochester, MN, USA
Blood 118:4992-9. 2011..In summary, lower-intensity heparin and standard-intensity warfarin anticoagulation are effective in preventing VTE recurrence... - Outcomes after withholding anticoagulation from patients with suspected acute pulmonary embolism and negative computed tomographic findings: a cohort studyStephen J Swensen
Department of Radiology, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:130-8. 2002..Withholding anticoagulation in these patients appears to be safe... - Is diabetes mellitus an independent risk factor for venous thromboembolism?: a population-based case-control studyJohn A Heit
Division of Cardiovascular Diseases, Section of Vascular Diseases, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Arterioscler Thromb Vasc Biol 29:1399-405. 2009..Consequently, we tested diabetes for an independent association with incident VTE... - Peri-procedural anticoagulation management of mechanical prosthetic heart valve patientsPaul R Daniels
Mayo Clinic Thrombophilia Center, Gonda Vascular Center, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA
Thromb Res 124:300-5. 2009.... - Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based studyJohn A Heit
Hematology Research, Stabile 660, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Arch Intern Med 162:1245-8. 2002..Greater emphasis should be placed on prophylaxis for hospitalized medical patients. Other recognized risk factors account for about 25% of all cases of venous thromboembolism, while the remaining 25% of cases are idiopathic... - Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based studyJohn A Heit
Mayo Clinic, Rochester, Minnesota 55905, USA
Ann Intern Med 143:697-706. 2005..Although the incidence of pulmonary embolism has decreased over time, the incidence of deep venous thrombosis remains unchanged, indicating the need to better identify pregnant women at increased risk... - Periprocedural anticoagulation management of patients with venous thromboembolismRobert D McBane
Gonda Thrombophilia Clinic, Mayo Clinic, 200 First Street SW, Rochester, MN 55902, USA
Arterioscler Thromb Vasc Biol 30:442-8. 2010..The incidence of thromboembolism and bleeding related to periprocedural anticoagulation management of such patients is unknown... - Estrogen, inflammation, and platelet phenotypeVirginia M Miller
Department of Surgery, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Gend Med 5:S91-S102. 2008..Although exogenous estrogenic therapies increase the risk of thrombosis, the effects of estrogen on formed elements of blood are uncertain... - Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillationWaldemar E Wysokinski
Thrombophilia Clinic, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:639-45. 2008.... - Characterization of blood borne microparticles as markers of premature coronary calcification in newly menopausal womenMuthuvel Jayachandran
Department of Surgery and Physiology and Biomedical Engineering, Mayo Clinic College of Medicine, 200 1st St SW, Rochester, MN 55905, USA
Am J Physiol Heart Circ Physiol 295:H931-H938. 2008..Therefore, the characterization of platelet and endothelial microparticles may identify early menopausal women with premature CAC who would not otherwise be identified by the usual risk factor analysis... - Incidence and cost burden of post-thrombotic syndromeAneel A Ashrani
Division of Hematology, Department of Internal Medicine, Stabile 6 60, Mayo Clinic, 200 First Street, Southwest, Rochester, MN 55905, USA
J Thromb Thrombolysis 28:465-76. 2009..Increasing the awareness of PTS, and the methods to prevent this complication may help reduce its incidence, improve long-term outcomes in patients, and decrease resulting costs associated with treatment... - Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura related to immune-mediated severe ADAMTS13-deficiency: a report of four cases and a systematic review of the literatureMischelle A Elliott
Department of Internal Medicine Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
Eur J Haematol 83:365-72. 2009..Prospective studies are urgently needed to define the true efficacy and long-term safety of rituximab... - Risk factors and underlying mechanisms for venous stasis syndrome: a population-based case-control studyAneel A Ashrani
Division of Hematology, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Vasc Med 14:339-49. 2009.... - Regional anesthesia in the patient receiving antithrombotic or thrombolytic therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Third Edition)Terese T Horlocker
Department of Anesthesiology, Mayo Clinic, Rochester, MN 55905, USA
Reg Anesth Pain Med 35:64-101. 2010..These are based on case reports, clinical series, pharmacology,hematology, and risk factors for surgical bleeding. An understanding of the complexity of this issue is essential to patient management... - Patent foramen ovale: innocent or guilty? Evidence from a prospective population-based studyIrene Meissner
Department of Neurology, Mayo Clinic, Rochester, Minnesota 55905, USA
J Am Coll Cardiol 47:440-5. 2006..We sought to determine the association between patent foramen ovale (PFO), atrial septal aneurysm (ASA), and stroke prospectively in a unselected population sample... - Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic considerationMichelle A Elliott
Division of Hematology Department of Internal Medicine, Mayo Clinic, Rochester, MN 55905, USA
Eur J Haematol 85:43-50. 2010..Recognition of cancer-associated microangiopathic hemolytic anemia with thrombocytopenia (CA-MHA) is paramount to avoid inappropriate PE therapy and delays in cancer-specific chemotherapy... - Impact of venous thromboembolism, venous stasis syndrome, venous outflow obstruction and venous valvular incompetence on quality of life and activities of daily living: a nested case-control studyAneel A Ashrani
Division of Hematology, Department of Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Vasc Med 15:387-97. 2010..VOO and VTE are associated with impaired ADL. We hypothesize that rapid clearance of venous outflow obstruction in individuals with acute VTE will improve their QoL and ADL... - Risk factors for venous thromboembolism in nursing home residentsCynthia L Liebson
Department of Health Sciences Research, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 83:151-7. 2008..To determine risk factors for venous thromboembolism (VTE) among nursing home (NH) residents... - Identifying in-hospital venous thromboembolism (VTE): a comparison of claims-based approaches with the Rochester Epidemiology Project VTE cohortCynthia L Leibson
Department of Health Sciences Research, Mayo Clinic College of Medicine, Rochester 55905, Minnesota, USA
Med Care 46:127-32. 2008..We estimated sensitivity, specificity, PPV, and negative predictive value (NPV) of claims-based approaches using the Rochester Epidemiology Project (REP) venous thromboembolism (VTE) cohort as a "gold standard.".. - Estrogen therapy and thrombotic riskVirginia M Miller
Department of Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, United States
Pharmacol Ther 111:792-807. 2006.... - Sensitivity and specificity of the semiquantitative latex agglutination D-dimer assay for the diagnosis of acute pulmonary embolism as defined by computed tomographic angiographyDavid A Froehling
Division of Area General Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 79:164-8. 2004.... - Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombinMichelle A Elliott
Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
Leuk Lymphoma 45:1545-9. 2004..021). These observations merit further study to gain insight into disease and/or therapy-specific pathogenesis of TE in this population and call for the prospective evaluation of appropriate prophylactic interventions... - Evaluation of a quantitative D-dimer latex immunoassay for acute pulmonary embolism diagnosed by computed tomographic angiographyDavid A Froehling
Division of General Internal Medicine, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA
Mayo Clin Proc 82:556-60. 2007..To determine the sensitivity and specificity of a quantitative plasma fibrin D-dimer latex immunoassay (LIA) for the diagnosis of acute pulmonary embolism... - Regional anesthesia in the anticoagulated patient: defining the risks (the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation)Terese T Horlocker
Department of Anesthesiology, Mayo Clinic, Rochester, Minnesota 55905, USA
Reg Anesth Pain Med 28:172-97. 2003 - Venous stasis syndrome: the long-term burden of deep vein thrombosisJohn A Heit
Mayo Clinic Thrombophilia Center, Department of Internal Medicine, Mayo Medical School, Mayo Clinic, Rochester, MN 55905, USA
Hosp Med 64:593-8. 2003..Prophylaxis with anticoagulant agents, including new drugs presently under investigation, may decrease the incidence and costs associated with this condition... - Warfarin sensitivity genotyping: a review of the literature and summary of patient experienceThomas P Moyer
Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
Mayo Clin Proc 84:1079-94. 2009.... - Venous thromboembolism epidemiology: implications for prevention and managementJohn A Heit
Division of Cardiovascular Diseases and Section of Hematology Research, Department of Internal Medicine, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
Semin Thromb Hemost 28:3-13. 2002..To reduce venous thromboembolism incidence, improve survival, and prevent recurrence and complications, patients with these characteristics should receive appropriate prophylaxis... - Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patientsCarrie A Thompson
Mayo Clinic College of Medicine, Rochester, Minnesota, USA
Am J Hematol 85:171-3. 2010..Optimal management of AL patients with FX deficiency undergoing invasive procedures remains to be determined... - Clinical importance of positive test results for lupus anticoagulant and anticardiolipin antibodiesAnne Proven
Division of Rheumatology and Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA
Mayo Clin Proc 79:467-75. 2004..Positive results were much more common for aCL than for LA. No single LA test or anticardiolipin isotype correlated with thrombosis or systemic disease in this population... - Risk factors for venous thromboembolismJohn A Heit
Division of Cardiovascular Diseases, Section of Vascular Diseases, Division of Hematology, Section of Hematology Research, Stabile 610, Department of Internal Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
Clin Chest Med 24:1-12. 2003.... - Iliac arterial thrombosis after inguinal hernia repairStephen F Van Buren
Division of Gastroenterologic and General Surgery, Mayo Clinic, Rochester, Minn 55905, USA
Mayo Clin Proc 77:1361-3. 2002.... - Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disordersRichard D Press
Department of Pathology and Medical Genetics, Oregon Health and Science University, Portland 97201, USA
Arch Pathol Lab Med 126:1304-18. 2002..As FVL is currently the most common recognized familial thrombophilia, it is hoped that these recommendations will assist laboratorians and clinicians caring for patients (and families) with this common mutation... - Prevention of venous thromboembolismWilliam Geerts
Chest 128:3775-6. 2005 - Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortalityAlexander T Cohen
Vascular Medicine, Department of Surgery, King s College Hospital, London, SE5 9RS, UK
Thromb Haemost 98:756-64. 2007..Given the availability of effective VTE prophylaxis, many of these events and deaths could have been prevented. These results have important implications for the allocation of healthcare resources... - Prophylaxis for the thromboembolic disease--recommendations from the American College of Chest Physicians--are they appropriate for orthopaedic surgery?Clifford W Colwell
J Arthroplasty 21:148-9; author reply 149. 2006 - Venous thromboembolism hospitalizations among American Indians and Alaska NativesW Craig Hooper
Hematologic Disease Branch, Division of AIDS, STD, and TB Laboratory Research, National Center for Infectious Diseases, Centers for Disease Control and Prevention, US Department of Health and Human Services, Atlanta, GA 30333, USA
Thromb Res 108:273-8. 2002..2 per 100,000) and lowest in the Alaska region (16.1 per 100,000). These data indicate that the overall VTE rate for AI/ANs may not have only decreased, but appears lower than the reported rate for Caucasians... - Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)William H Geerts
Thromboembolism Program, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada
Chest 133:381S-453S. 2008..We recommend that, on admission to the ICU, all patients be assessed for their risk of VTE, and that most receive thromboprophylaxis (Grade 1A)... - Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolismFrederick A Anderson
Center for Outcomes Research, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
Am J Hematol 82:777-82. 2007..Given the existence of internationally-accepted evidence-based guidelines for prevention of VTE, research is required to establish if this patient population is receiving recommended VTE prophylaxis... - Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyWilliam H Geerts
Thromboembolism Program, Sunnybrook and Women's College Health Sciences Centre, Room D674, 2075 Bayview Ave, Toronto, ON, Canada M4N 3M5
Chest 126:338S-400S. 2004..We recommend, on admission to the intensive care unit, all patients be assessed for their risk of VTE. Accordingly, most patients should receive thromboprophylaxis (Grade 1A)... - The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patientsNiranjan Seshadri
Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
Am Heart J 150:27-34. 2005..Future large-scale, randomized trials are warranted... - The potential role of fondaparinux as venous thromboembolism prophylaxis after total hip or knee replacement or hip fracture surgeryJohn A Heit
Arch Intern Med 162:1806-8. 2002
Research Grants
- Individual Propensity to Venous ThrombosisJohn Heit; Fiscal Year: 2009..However, the incidence of VTE has remained relatively constant at about 1 per 1000 since 1980. Clearly, better methods of targeting VTE prophylaxis are needed. ..
- Mayo Clinic Vascular Medicine Clinical Research Training ProgramJohn Heit; Fiscal Year: 2007..In addition, this research will teach doctors how to discover new causes of diseases of arteries, veins and lymph vessels, as well as new ways to prevent and treat these diseases. ..
- RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN THE COMMUNITYJohn Heit; Fiscal Year: 2007..This data will provide insights regarding the effect of new prophylaxis drugs on VTE incidence and why some but not most high-risk patients develop VTE, and test the effect of outpatient LMWH therapy on VTE recurrence. ..
- Individual Propensity to Venous ThrombosisJohn Heit; Fiscal Year: 2007..However, the incidence of VTE has remained relatively constant at about 1 per 1000 since 1980. Clearly, better methods of targeting VTE prophylaxis are needed. ..
- RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN THE COMMUNITYJohn Heit; Fiscal Year: 2004..Finally, the investigators will plan to extend their analysis of current VTE in relationship to use of standard heparin and low molecular weight heparin. ..
- RISK FACTORS FOR VENOUS THROMBOEMBOLISM IN THE COMMUNITYJohn A Heit; Fiscal Year: 2010..This study aims to prevent these deaths by identifying the individual person at high risk and preventing venous thromboembolism. ..